pSivida Corp., of Watertown, Mass., and Alimera Sciences Inc., of Atlanta, reported 36-month, top-line results for the FAME study of Iluvien in diabetic macular edema, showing statistically significant therapeutic effects with 28.9 percent at month 30 (p = 0.011) and 28.4 percent at month 33 (p = 0.042) of Iluvien patients gaining 15 or more letters compared to the control group, in which fewer than 17 percent of patients gained 15 or more letters.